COX-2 in cardiovascular disease

被引：48

作者：

Bishop-Bailey, D

Mitchell, JA

Warner, TD

机构：

[1] Queen Mary Univ London, William Harvey Res Inst, London EC1M 6BQ, England

[2] Imperial Coll Sch Med, Royal Brompton Hosp, Natl Heart & Lung Inst, Unit Crit Care Med, London, England

来源：

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2006年 / 26卷 / 05期

关键词：

D O I：

10.1161/01.ATV.0000219672.68024.bc

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：956 / 958

页数：3

共 21 条

[1] Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation - The nonsteroidal anti-inflammatory drugs in unstable angina treatment-2 (NUT-2) pilot study [J].

Altman, R ;

Luciardi, HL ;

Muntaner, J ;

Del Rio, F ;

Berman, SG ;

Lopez, R ;

Gonzalez, C .

CIRCULATION, 2002, 106 (02) :191-195

[2] Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages [J].

Baker, CSR ;

Hall, RJC ;

Evans, TJ ;

Pomerance, A ;

Maclouf, J ;

Creminon, C ;

Yacoub, MH ;

Polak, JM .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (03) :646-655

[3] Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis [J].

Belton, OA ;

Duffy, A ;

Toomey, S ;

Fitzgerald, DJ .

CIRCULATION, 2003, 108 (24) :3017-3023

[4] Induction of cyclooxygenase-2 in human saphenous vein and internal mammary artery [J].

BishopBailey, D ;

Pepper, JR ;

Haddad, EB ;

Newton, R ;

Larkin, SW ;

Mitchell, JA .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (09) :1644-1648

[5] Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].

Bombardier, C ;

Laine, L ;

Reicin, A ;

Shapiro, D ;

Burgos-Vargas, R ;

Davis, B ;

Day, R ;

Ferraz, MB ;

Hawkey, CJ ;

Hochberg, MC ;

Kvien, TK ;

Schnitzer, TJ ;

Weaver, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528

[6] Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].

Bresalier, RS ;

Sandler, RS ;

Quan, H ;

Bolognese, JA ;

Oxenius, B ;

Horgan, K ;

Lines, C ;

Riddell, R ;

Morton, D ;

Lanas, A ;

Konstam, MA ;

Baron, JA .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102

[7] Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice [J].

Burleigh, ME ;

Babaev, VR ;

Oates, JA ;

Harris, RC ;

Gautam, S ;

Riendeau, D ;

Marnett, LJ ;

Morrow, JD ;

Fazio, S ;

Linton, MF .

CIRCULATION, 2002, 105 (15) :1816-1823

[8]

Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735

[9] Cyclooxygenases, thromboxane, and atherosclerosis -: Plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism [J].

Egan, KM ;

Wang, M ;

Lucitt, MB ;

Zukas, AM ;

Puré, E ;

Lawson, JA ;

FitzGerald, GA .

CIRCULATION, 2005, 111 (03) :334-342

[10]

ELDOR A, 1981, J CLIN INVEST, V67, P735, DOI 10.1172/JCI110090

← 1 2 3 →